5-Amino-1MQ Dosage Chart & Schedule Guide.

No, and this trips up almost everyone who finds it on a peptide site. It is a small-molecule quinolinium salt: IUPAC name 1-methylquinolin-1-ium-5-amine, CAS 42464-96-0, molecular weight 159.21 for the cation and around 286 for the iodide salt commonly supplied. It has no amino acids and no peptide bonds. That is why it can be swallowed at all, and why it behaves like a small-molecule drug: real oral absorption, first-pass liver metabolism, a huge volume of distribution (39 L/kg in mice), and off-target enzyme binding. It gets grouped with peptides purely because it is sold through the same channels.

For most people, capsules. The injectable format is genuinely awkward here: a 50 mg vial lasts only ten days at 5 mg/day, so you are buying three vials a month to inject a compound that is orally active. The one real argument for injecting is bypassing first-pass metabolism, and the strength of that argument depends entirely on which bioavailability study you believe (3.5% in mice versus 38.4% in rats). Every efficacy study (obesity, liver, muscle) used subcutaneous dosing, so injection is the route with the animal evidence behind it. Capsules are the route with the human track record, such as it is.

Because it is a different route, not a different strength. Swallowed 5-Amino-1MQ has to survive gut absorption and a heavy first pass through the liver; injected, essentially all of it reaches circulation. If the mouse figure of 3.5% oral bioavailability holds in humans, 100 mg swallowed delivers roughly 3.5 mg systemically, which is why 100 mg oral and 5 mg subcutaneous end up as the two standard protocols. Never treat the numbers as interchangeable in the syringe.

The honest answer is that this has barely been tested cleanly. The most dramatic result (mice returning to a body composition indistinguishable from lean age-matched animals) came from combining the inhibitor with a low-fat diet switch, and that study did not include a drug-alone arm. What the drug-alone data does show is that mice lost fat with no change in food intake, so the effect is not simply appetite suppression. And the muscle study found the compound and exercise were additive rather than interchangeable. Treat it as an amplifier of what you are already doing.

The 8 – 12 weeks on, 4 weeks off convention is not derived from any study; it comes from community practice, and the rationale usually given (letting NNMT expression reset, avoiding tolerance) has never been demonstrated for this compound. The defensible reason to cap a cycle at 12 weeks is simply that no one has taken a methylation-pathway enzyme inhibitor for longer than that under observation. NNMT sits on the same one-carbon metabolism that governs SAM, homocysteine and DNA methylation, and the long-term consequences of suppressing it are unstudied. The break is a hedge against an unknown, not a pharmacological requirement.

There is no interaction study, so nobody can give you a data-backed answer. Mechanistically they do not overlap (GLP-1 agonists work through appetite and gastric emptying, this works on adipocyte lipogenesis and NAD+), and the mouse data specifically showed fat loss without reduced food intake, so they are not redundant. The practical concern is additive nausea and additive appetite loss during the GLP-1 titration phase, and the real risk of losing lean mass if intake drops too far. If you combine them, do not start both at once, and keep protein and resistance training up.

Serious enough to change who should use it, not serious enough to rule it out for everyone. It was a single in-vitro screen at 10 µM (a concentration that may sit well above what a 5 mg dose produces in your tissues), so it is not proof you are taking an MAOI. But the study authors named it explicitly as an off-target activity they are working to engineer out, and even speculated that some of the glucose-tolerance benefit might come from it. Nobody has measured whether ordinary human doses reach MAO-A-inhibiting concentrations. Given that, the sensible position is to treat the drug-interaction contraindications as firm, particularly antidepressants and stimulants, while accepting that for someone on no such medications the risk is likely small but genuinely unquantified.

The fat loss is not self-sustaining, because the mechanism is reversible enzyme inhibition; once the compound clears, NNMT resumes normal activity. No washout study exists for 5-Amino-1MQ, so how quickly things drift back is unknown. What does carry over is anything structural you built during the cycle: muscle, training capacity, insulin sensitivity gains that follow from lower fat mass, and eating patterns you can maintain. People who lose fat on a cycle and then return to their previous habits generally regain it. People who use the cycle to establish a routine they would have kept anyway tend to hold most of the change.